Life Science News

Applied UV, Inc. (NasdaqCM: AUVI ) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announces that John F. Andrews has joined the Company serving as Chief Executive Officer and a member of the Board of Directors.

John F. Andrews has over 30 years of senior leadership experience in telecom and technology companies, both public and private. He has been CEO of several public companies as well as started and founded companies from ground zero. His experience includes leading three (3) companies to strategic exits (two (2) private and one (1) public), raising over one hundred (100) million dollars of public and private capital, managing numerous mergers and acquisitions, leading companies through explosive growth as well as rightsizing, and being recruited to turn around stalled companies. He recently was the CEO and Co-founder of Trinity IT Services LLC and CEO of TrekSecure LLC. A seasoned executive, his experience also includes being Chairman and EVP of ShipXpress which GE acquired, being CEO of Giga (NASDAQ GIGA) where he led the company's sale to Forrester Research (NASDAQ FORR) and being the CEO of e-Medsoft which went public. His fortune 300 corporate experience includes being CIO and SVP of CSX Transportation at CSX (NASDAQ CSX) corporation managing thousands of employees. During his tenure at CSX, he was credited in achieving over five hundred (500) million dollars in operating expense reductions through his visionary and portfolio technology projects. As CIO he received several industry awards to include CIO of the year from Information Week and top industry visionary from Computerworld. While at CSX, Andrews also consulted with Sun Microsystems (NASDAQ SUNW) on the development of JAVA. Prior to CSX Andrews held executive positions with telecom giant GTE, to include division CIO, President Government Information Systems and President Healthcare Information Systems. Andrews has an MBA from the University of Puget-Sound, Seattle WA, and a BA, Business Administration and Finance from Whitworth University, Spokane WA.

Joel Kanter, Applied UV's Chairman of the Board, stated, "We are thrilled to have been able to attract John to Applied UV. While the Company has completed a lot of ‘foundational building' in the last year with the multiple acquisitions and offerings, now it is time to move to the ‘building phase' when we hope to be better disciplined in choosing our opportunities, and generate the disciplined growth we hoped would result from the accumulation of superb products. John's vast experience in growing superb and focused teams, that are then able to engender the growth we and our shareholders believe is possible, is a huge step forward in ultimately seeing these hopes become a reality. We look forward with great excitement to what will be achieved in the coming months and years."

John Andrews states, "I am thrilled to have the opportunity of leading Applied UV at this most important time for the company as we are in position to accelerate our growth in the global air purification and pathogen elimination market. The growing market tailwinds created by the recent government initiatives, guidelines and policies surrounding improving indoor air, Applied UV's best in class suite of air purification technologies is well suited to fill this growing global demand of cleaner in-door air and pathogen elimination. I look forward to working together with our Board of Directors, senior executives, employees, and consultants as we embark upon this journey."

About Applied UV

Applied UV is focused on the development and acquisition of technology that address infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. ("SteriLumen") and Munn Works, LLC ("Munn Works"). SteriLumen's connected platform for Data Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company's Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices' proximity. The Company's patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen intensive location. SteriLumen's Airocide ® air purification devices are research backed, clinically proven and developed for NASA with assistance from the University of Wisconsin. Airocide ® is listed as an FDA Class II Medical device, utilizes a proprietary photocatalytic (PCO) bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous airborne pathogens, destructive VOCs, allergens, odors and biological gasses into harmless water vapor and green carbon dioxide without producing ozone or other harmful byproducts. Airocide ® applications include healthcare, hospitality, grocery chains, wine making facilities, commercial real estate, schools, dental offices, post-harvest, grocery, cannabis facilities and homes. For more information about Applied UV, Inc., and its subsidiaries, please visit the following websites: https://www.applieduvinc.com/ ; https://sterilumen.com/ ; https://www.airocide.com https://kesscience.com ; https://scientificairmanagement.com and, https://munnworks.com/ .

Forward-Looking Statements

The information contained herein may contain "forward‐looking statements." Forward‐looking statements reflect the current view about future events. When used in this press release, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Applied UV concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward‐looking statements are based on the Company's current expectations and assumptions regarding its business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward‐looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward‐looking statements. Factors or events that could cause the Company's actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward‐looking statements to conform these statements to actual results.

For additional Company Information:
Applied UV Inc.
John F. Andrews
Applied UV CEO, Director
john.andrews@applieduvinc.com

Brett Maas, Managing Principal
Hayden IR
brett@haydenir.com
(646) 536-7331

News Provided by Business Wire via QuoteMedia

AUVI:NSD
Applied UV

Applied UV


Keep reading...Show less

Viemed Announces Publication of Peer-Reviewed NIVH Study Finding Treatment Reduces Healthcare Costs and Saves Lives

Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD and TSX:VMD.TO), a national leader in respiratory care and technology-enabled home medical equipment services, announced a third peer-reviewed and published study demonstrating the benefits of non-invasive ventilation at home ("NIVH"). The study, titled "Early Initiation of Non-Invasive Ventilation at Home Improves Survival and Reduces Healthcare Costs in COPD Patients with Chronic Hypercapnic Respiratory Failure: A Retrospective Cohort Study" was published in Respiratory Medicine an internationally renowned scientific journal devoted to respiratory medical research.

"In addition to the significant clinical benefits demonstrated in previously published papers, this study demonstrates that NIVH improves health outcomes while simultaneously driving down overall healthcare costs," said Dr. William Frazier, Viemed's Chief Medical Officer and co-author of the study. "The study was also designed to investigate how the timing of NIVH initiation affected the outcomes. The results showed that the clinical and financial benefits of NIVH are greatest when therapy begins immediately following the diagnosis."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 28, 2022

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2022 before the market opens on Thursday, July 28, 2022, and will hold a conference call on the same day at 8:30 a.m. EDT.

During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (844) 200-6205 within the U.S. or (929) 526-1599 outside the U.S. The access code is 512129. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com . The earnings press release and related information can be found in that section of our website under "Earnings Results." A replay of the call will be available under "News and Events" through Friday, August 12, 2022.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Knight Therapeutics announces relaunch of AKYNZEO® in Brazil

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., is assuming full commercial activities and is relaunching AKYNZEO ® (netupitant palonosetron) in Brazil.

On May 12, 2022 Knight and Helsinn Healthcare SA ("Helsinn") announced they have entered into an exclusive license, distribution and supply agreement for oral/IV AKYNZEO ® in Canada, Brazil, Argentina, Uruguay and Paraguay, and ALOXI ® oral/IV (palonosetron) in Canada (the "Products").

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
How Do Medical Devices Get Approved?

How Do Medical Devices Get Approved?

Life science investors are familiar with the arduous path new drugs must go through to reach the market. But how do medical devices get approved?

In terms of devices, the same rigorous testing and inspection are required from regulatory agencies. The US Food and Drug Administration (FDA) is the agency tasked with reviewing new devices and making amendments to already approved devices.

More specifically, medical device approval is done through the FDA’s Center for Devices and Radiological Health (CDRH). The CDRH looks after the entire regulation process for companies that manufacture, repackage, relabel and import devices to the US.

Keep reading...Show less

Danaher Announces Appointment of Feroz Dewan to Danaher Board

Danaher Corporation (NYSE: DHR) announced today that it has appointed Feroz Dewan to its Board of Directors and to the Board's Science & Technology Committee. This addition expands the size of Danaher's Board from thirteen to fourteen members.

Mr. Dewan is currently CEO of Arena Holdings Management, a global investment business. From 2003 to 2015, he worked at Tiger Global Management, most recently as Head of Public Equities. Prior to that, Mr. Dewan was a private equity investor at Silver Lake Partners.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Abbott Hosts Conference Call for Second-Quarter Earnings

Abbott (NYSE: ABT) will announce its second-quarter 2022 financial results on Wednesday, July 20, 2022 before the market opens.

The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time ( 9 a.m. Eastern), and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com . An archived edition of the call will be available later that day.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×